Q2 2026 Preview: 6 FDA Decisions to Watch
The first quarter of 2026 established a brisk regulatory pace that Q2 shows no signs of slowing. In the span of 3 months, the United States Food and Drug Administration (US FDA) cleared deucravacitinib for psoriatic arthritis (PsA) — the first TYK2 …